Entrar/Registro  
INICIO ENGLISH
 
Medicina Cutánea Ibero-Latino-Americana
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio


ENVÍO DE ARTÍCULOS






>Revistas >Medicina Cutánea Ibero-Latino-Americana >Año 2015, No. 2


Guerra TA, de Lucas LR, Moreno GJC, Pérez LM, Ribera PM, Martínez PE, Senan SR, Casas RJ
Consenso en el tratamiento tópico del acné
Med Cutan Iber Lat Am 2015; 43 (2)

Idioma: Español
Referencias bibliográficas: 137
Paginas: 104-121
Archivo PDF: 537.59 Kb.


Texto completo




RESUMEN

El tratamiento tópico del acné puede llevarse a cabo mediante diferentes grupos terapéuticos y sus combinaciones o asociaciones, así como con los antibióticos, los retinoides, el peróxido de benzoílo, el ácido salicílico, los alfa hidroxiácidos, la sulfacetamida sódica, el ácido azelaico, e incluso cosméticos y cosmecéuticos. Del mismo modo, hay que tener en cuenta el tipo de lesión predominante (comedón, pápulas, pústulas, cicatrices), el nivel de gravedad y el carácter inflamatorio o no inflamatorio del conjunto. Tanto en la fase activa moderada o leve en la que no es preciso el tratamiento sistémico, como en los casos más graves de acné como adyuvante, o en los momentos posteriores de mantenimiento, una adecuada terapéutica tópica puede ser de suma importancia en la evolución del cuadro clínico y en la mejora de la calidad de vida. En este contexto se analizan las moléculas, indicaciones, posología y efectos secundarios desde el punto de vista de la evidencia científica, logrando un consenso multidisciplinario entre dermatólogos, pediatras y médicos de atención primaria en el tratamiento tópico del acné.


Palabras clave: Acné, tratamiento tópico, antibióticos, retinoides, peróxido de benzoílo, ácido salicílico, asociaciones, alfa hidroxiácidos, sulfacetamida sódica, ácido azelaico, cosméticos, consenso.


REFERENCIAS

  1. Guerra-Tapia A, Puig-Sanz L, Conejo Mir J, Toribio-Pérez J, Iglesias C, Zsolt I. Factibilidad y fiabilidad de la versión española de la escala revisada de gravedad de Leeds (LRAG) para pacientes con acné. Actas Dermosifiliogr. 2010; 101: 778-784.

  2. Guerra TA, Camacho FM. Aspectos psíquicos del acné. Influencia terapéutica. Monogr Dermatol. 2008; 21: 11-123.

  3. Rivera R, Guerra TA. Manejo del acné en mujeres mayores de 25 años. Actas Dermosifiliogr. 2008; 100: 33-37.

  4. Nast A, Dreno B, Bettoli V, Degitz K, Erdmann R, Finlay AI et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012; 26 (Suppl 1): 1-29.

  5. Ribera M, Guerra A, Moreno-Giménez JC, de Lucas R, Pérez-López M. Tratamiento del acné en la práctica clínica habitual: encuesta de opinión entre los dermatólogos españoles. Actas Dermosifiliogr. 2011; 102: 121-131.

  6. Narahari S, Gustafson CJ, Feldman SR. What’s new in antibiotics in the management of acne? G Ital Dermatol Venereol. 2012; 147: 227-238.

  7. Kinney MA, Yentzer BA, Fleischer AB Jr, Feldman SR. Trends in the treatment of acne vulgaris: are measures being taken to avoid antimicrobial resistance? J Drugs Dermatol. 2010; 9: 519-524.

  8. Patel M, Bowe WP, Heughebaert C, Shalita AR. The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. J Drugs Dermatol. 2010; 9: 655-664.

  9. Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita MD, Siegfried EC, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007; 56: 651-663.

  10. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin⁄tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol. 2006; 54: 73-81.

  11. Tschen EH, Katz HI, Jones TM, Monroe EW, Kraus SJ, Connolly MA et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis. 2001; 67: 165-169.

  12. Blaney DJ, Cook CH. Topical use of tetracycline in the treatment of acne: a double-blind study comparing topical and oral tetracycline therapy and placebo. Arch Dermatol. 1976; 112: 971-973.

  13. Mills O Jr, Thornsberry C, Cardin CW, Smiles KA, Leyden JJ. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol. 2002; 82: 260-265.

  14. Llorca M, Hernandez-Gill A, Ramos M. Erythromycin laurilsulfate in the topical treatment of acne vulgaris. Curr Ther Res. 1982; 32: 14-20.

  15. Adişen E, Kaymak Y, Gurer MA, Durukan E. Topical tetracycline in the treatment of acne vulgaris. J Drugs Dermatol. 2008; 7: 953-955.

  16. Keri J, Shiman M. An update on the management of acne vulgaris. Clin Cosmet Investig Dermatol. 2009; 2:105-10.

  17. Kuwahara K, Kitazawa T, Kitagaki H, Tsukamoto T, Kikuchi M. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J Dermatol Sci. 2005; 38: 47-55.

  18. Sato T, Shirane T, Noguchi N, Sasatsu M, Ito A. Novel anti-acne actions of nadifloxacin and clindamycin that inhibit the production of sebum, prostaglandin E(2) and promatrix metalloproteinase-2 in hamster sebocytes. J Dermatol. 2012; 39: 774-778.

  19. Eady EA, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? Implication of resistance for acne patients and prescribers. Am J Clin Dermatol. 2003; 4: 813-831.

  20. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a world-wide problem. Dermatology. 2003; 206: 54-56.

  21. Ross JI, Snelling AM, Eady EA, Cove JH, Cunliffe WJ, Leyden JJ et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the USA, Japan and Australia. Br J Dermatol. 2001; 144: 339-346.

  22. Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol. 2003; 148: 467-478.

  23. Nord CE, Oprica C. Antibiotic resistance in Propionibacterium acnes. Microbiological and clinical aspects. Anaerobe. 2006; 12: 207-210.

  24. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol. 2005; 153: 395-403.

  25. Krautheim A, Gollnick HP. Acne: topical treatment. Clin Dermatol. 2004; 22: 398-407.

  26. Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust. 1998; 169: 259-261.

  27. Tunca M, Akar A, Ozmen I, Erbil H. Topical nadifloxacin 1% cream vs. topical erythromycin 4% gel in the treatment of mild to moderate acne. Int J Dermatol. 2010; 49: 1440-1444.

  28. Lookingbill DP, Chalker DK, Lindholm JS, Katz HI, Kempers SE, Huerter CJ et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol. 1997; 37: 590-595.

  29. Tan J. Dapsone 5% gel: a new option in topical therapy for acne. Skin Therapy Lett. 2012; 17: 1-3.

  30. Reichrath J, Lehmann B, Carlberg C, Varani J, Zouboulis CC. Vitamins as hormones. Horm Metabg Res. 2007; 39: 71-84.

  31. Do Nascimento LV, Guedes AC, Magalhaes GM, de Faria FA, Guerra RM, de C Almeida F. Single-blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. J Dermatolog Treat. 2003; 14: 166-171.

  32. Sorg O, Antille C, Kaya G, Saurat JH, Retinoids in cosmeceuticals. Dermatologic Therapy. 2006; 19: 289-296.

  33. Soria Gili X, Ribera Pibernat M. Biology of retinoid receptors. Piel. 2005; 20: 68-73.

  34. Thiboutot D, Pariser DM, Egan N, Flores J, Herndon JH Jr, Kanof NB et al. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol. 2006; 54: 242-250.

  35. Pariser DM, Thiboutot DM, Clark SD, Jones TM, Liu Y, Graeber M. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: a randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. Cutis. 2005; 76: 145-151.

  36. Lucky AW, Jorizzo JL, Rodríguez D, Jones TM, Stewart DM, Tschen EH et al. Efficacy and tolerance of adapalene cream 0.1% compared with its cream vehicle for the treatment of acne vulgaris. Cutis. 2001; 68: 34-40.

  37. Kawashima M, Harada S, Loesche C, Miyachi Y. Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris: a randomized, multicenter, investigator-blinded, controlled study. J Dermatol Sci. 2008; 49: 241-248.

  38. Chalker DK, Lesher JL Jr, Smith JG Jr, Klauda HC, Pochi PE, Jacoby WS et al. Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, double-blind investigation. J Am Acad Dermatol. 1987; 17: 251-254.

  39. Berger R, Barba A, Fleischer A, Leyden JJ, Lucky A, Pariser D et al. A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults. Cutis. 2007; 80: 152-157.

  40. Lucky AW, Cullen SI, Jarratt MT, Quigley JW. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol. 1998; 38: S17-S23.

  41. Nagpal S, Saunders M, Kastner P, Durand B, Nakshatri H, Chambon P et al. Promoter context -and response element- dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors. Cell. 1992; 70: 1007-1019.

  42. Korkut C, Piskin S. Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. J Dermatol. 2005; 32: 169-173.

  43. Gollnick HP, Draelos Z, Glenn MJ et al. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol. 2009; 161: 1180-1189.

  44. Stinco G, Bragadin G, Trotter D, Pillon B, Patrone P. Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. J Eur Acad Dermatol Venereol. 2007; 21: 320-325.

  45. Hughes BR, Norris JF, Cunliffe WJ. A double-blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clin Exp Dermatol. 1992; 17: 165-168.

  46. Bucknall JH, Murdoch PN. Comparison of tretinoin solution and benzoyl peroxide lotion in the treatment of acne vulgaris. Curr Med Res Opin. 1977; 5: 266-268.

  47. Lyons RE. Comparative effectiveness of benzoyl peroxide and tretinoin in acne vulgaris. Int J Dermatol. 1978; 17: 246-251.

  48. Gollnick HP, Graupe K, Zaumseil RP. Azelaic acid 15% gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. J Dtsch Dermatol Ges. 2004; 2: 841-847.

  49. Thiboutot D, Gold MH, Jarratt MT, Kang S, Kaplan DL, Millikan L et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis. 2001; 68: 10-19.

  50. Tu P, Li GQ, Zhu XJ, Zheng J, Wong WZ. A comparison of adapalene gel 0.1% versus tretinoin gel 0.025% in the treatment of acne vulgaris in China. J Eur Acad Dermatol Venereol. 2001; 15 (Suppl 3): 31-36.

  51. Grosshans E, Marks R, Mascaro JM, Torras H, Meynadier J, Alirezai M et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol. 1998; 139 (Suppl 52): 26-33.

  52. Cunliffe WJ, Danby FW, Dunlap F, Gold MH, Gratton D, Greenspan A. Randomized, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris. Eur J Dermatol. 2002; 12: 350-354.

  53. Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% versus isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. Br J Dermatol. 2002; 147: 523-527.

  54. Domínguez J, Hojyo MT, Celayo JL, Domínguez-Soto L, Teixeira F. Topical isotretinoin versus topical retinoic acid in the treatment of acne vulgaris. Int J Dermatol. 1998; 37: 54-55.

  55. Glass D, Boorman GC, Stables GI, Cunliffe WJ, Goode K. A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. Dermatology. 1999; 199: 242-247.

  56. Langner A, Boorman GC, Stapor V. Isotretinoin cream 0.05% and 0.1% in the treatment of acne vulgaris. J Dermatol Treat. 1994; 5: 177-180.

  57. Lucky AW, Cullen SI, Funicella T, Jarratt MT, Jones T, Reddick ME. Double-blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol. 1998; 38: S24-S30.

  58. Nyirady J, Grossman RM, Nighland M, Berger RS, Jorizzo JL, Kim YH et al. A comparative trial of two retinoids commonly used in the treatment of acne vulgaris. J Dermatolog Treat. 2001; 12: 149-157.

  59. Zouboulis CC, Fischer TC, Wohlrab J, Barnard J, Alio AB. Study of the efficacy, tolerability, and safety of 2 fixed-dose combination gels in the management of acne vulgaris. Cutis. 2009; 84: 223-229.

  60. Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Arsonnaud S, Kang S. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed. 2005; 4: 138-146.

  61. Kircik L, Green L, Thiboutot D, Tanghetti E, Wilson D, Dhawan S. Comparing a novel solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin: final data from a multicenter, investigator-blind, randomized study. J Drugs Dermatol. 2009; 8: 812-818.

  62. Kircik L, Wilson D, Dhawan S. Solubilized benzoyl peroxide versus benzoyl peroxide/clindamycin in the treatment of moderate acne. J Drugs Dermatol. 2008; 7: 534-538.

  63. Gold LS, Tan J, Cruz-Santana A, Papp K, Poulin Y, Schlessinger J, Gidner J. A North American study of adapalene-benzoylperoxide combination gel in the treatment of acne. Cutis. 2009; 84: 110-116.

  64. Alirezai M, George SA, Coutts I, Roseeuw DI, Hachem JP, Kerrouche N. Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline. Eur J Dermatol. 2007; 17: 45-51.

  65. Weinstock AA, Bigham SF, Lew RA, Hall R, Eilers D, Kirsner R, Naylor M. Topical tretinoin therapy and all-cause mortality. Arch Dermatol. 2009; 145: 15-24.

  66. Bowe WP, Shalita AR. Effective over-the-counter acne treatments. Semin Cutan Med Surg. 2008; 27: 170-176.

  67. Worret WI, Fluhr JW. Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. J Dtsch Dermatol Ges. 2006; 4: 293-300.

  68. Food and drug administration, HHS. Classification of benzoyl peroxide as safe and effective and revision of labelling to drug facts format; topical acne drug products for over-the-counter human use; final rule. Fed Regist. 2010; 75: 9767-9777.

  69. Fluhr JW, Degitz K. Antibiotics, azelaic acid and benzoyl peroxide in topical acne therapy. J Dtsch Dermatol Ges. 2010; 8 (Suppl 1): S24-S30.

  70. Waller JM, Dreher F, Behnam S, Ford C, Lee C, Tiet T et al. Keratolitic properties of benzoyl peroxide and retinoic acid resemble: salicylic acid in man. Skin Pharmacol Physiol. 2006; 19: 283-289.

  71. Tanghetti E. The evolution of benzoyl peroxide therapy. Cutis. 2008; 82 (Suppl 5): 5-11.

  72. Del Rosso JQ, Kim G. Optimizing use of oral antibiotics in acne vulgaris. Dermatol Clin. 2009; 27: 33-42.

  73. Sagransky M, Yentzer BA, Feldman SR. Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Expert Opin Pharmacother. 2009; 15: 2555-2562.

  74. Tanghetti EA, Popp KF. A current review of topical benzoyl peroxide: new perspectives on formulation and utilization. Dermatol Clin. 2009; 27: 17-24.

  75. Bikowski J. A review of the safety and efficacy of benzoyl peroxide (5.3%) emollient foam in the management of truncal acne vulgaris. J Clin Aesthet Dermatol. 2010; 3: 26-29.

  76. Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol. 2007; 57: 791-799.

  77. Gamble R, Dunn J, Dawson A, Petersen B, McLaughlin L, Small A, Kindle S, Dellavalle RP. Topical antimicrobial treatment of acne vulgaris: an evidence-based review. Am J Clin Dermatol. 2012; 13: 141-152.

  78. Seidler EM, Kimball AB. Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. J Am Acad Dermatol. 2010; 63: 52-62.

  79. Ingram JR, Grindlay DJ, Williams HC. Management of acne vulgaris: an evidence-based update. Clin Exp Dermatol. 2010; 35: 351-354.

  80. Simpson RC, Grindlay DJ, Williams HC. What’s new in acne? An analysis of systematic reviews and clinically significant trials published in 2010-11. Clin Exp Dermatol. 2011; 36: 840-843.

  81. Fakhouri T, Yentzer BA, Feldman SR. Advancement in benzoyl peroxide-based acne treatment: methods to increase both efficacy and tolerability. J Drugs Dermatol. 2009; 8: 657-661.

  82. Brandstetter AJ, Maibach HI. Topical dose justification: benzoyl peroxide concentrations. J Dermatolog Treat. 2011; Dec. 27. [Epub ahead of print].

  83. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012; 379: 361-372.

  84. Thiele JJ. Oxidative tarjets in the stratum corneum. A new basis for antioxidative strategies. Skin Pharmacol Appl Skin Physiol. 2001; 14 (Suppl 1): 87-91.

  85. Kircik L, Friedman A. Optimizing acne therapy with unique vehicles. J Drugs Dermatol. 2010; 5 (Suppl): 53-57.

  86. Ceilley RI. Advances in topical delivery systems in acne: new solutions to address concentration dependent irritation and dryness. Skinmed. 2011; 9: 15-21.

  87. Dutil M. Benzoyl peroxide: enhancing antibiotic efficacy in acne management. Skin Therapy Lett. 2010; 15: 5-7.

  88. Gollnick H, Cunliffe W, Berson DDreno B, Finlay A, Leyden JJ et al. Management of acne: a report from a Global Alliance to improve outcomes in acne. J Am Acad Dermatol. 2003; 49: S1-38.

  89. Guerra-Tapia A. Effects of benzoyl peroxide 5%/clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single-blind study. J Drugs Dermatol. 2012; 11: 466-474.

  90. Katsambas A, Stefanaki C, Cunliffe W. Guidelines for treating acne. Clin Dermatol. 2004; 22: 439-444.

  91. Weirich EG. Dermatopharmacology of salicilic acid. Dermatologica. 1975; 151: 268-273.

  92. Hjorth N. Traditional topical treatment of acne. Acta Derm Venereol (Stockh). 1980; 89 (Suppl): 53-56.

  93. Olsen TG. Therapy of acne. Med Clin North Am. 1982; 66: 851-871.

  94. Shalita AR. Treatment of mild and moderate acne vulgaris with salicyli acid in an alcohol-detergent vehicle. Cutis. 1981; 28: 556-8, 561.

  95. Zander E, Weisman S. Treatment of acne vulgaris with salicylic acid pads. Clin Ther. 1992; 14: 247-253.

  96. Mammone T, Gan D, Goyarts E, Maes D. Salicylic acid protects the skin from UV damage. J Cosmet Sci. 2006; 57: 203-204.

  97. Fetil E, Ozka S, Soyal MC, Ilknur T, Erdem Y, Güneş AT. Effects of topical petrolatum and salicylic acid on the erythemogenicity of UVB. Eur J Dermatol. 2002; 12: 154-156.

  98. Levesque A, Hamzavi I, Seite S, Rougier A, Bissonnette R. Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. J Cosmet Dermatol. 2011; 10: 174-178.

  99. Schwarb FP, Gabard B, Rufli T, Surber C. Percutaneous absorption of salicylic acid in man after topical administration of three different formulations. Dermatology. 1999; 198: 44-51.

  100. Bashir SJ, Dreher F, Chew AL, Zhai H, Levin C, Stern R, Maibach HI. Cutaneous bioassay of salicylic acid as a keratolytic. Int J Pharm. 2005; 292: 187-194.

  101. Pertoldi F, D’Orlando L, Mercante WP. Acute salicylate intoxication after trancutaneous absorption. Minerva Anestesiol. 1999; 65: 571-573.

  102. Raschke R, Arnold-Capell PA, Richeson R, Curry SC. Refractory hypoglycemia secondary to topical salicylate intoxication. Arch Intern Med. 1991; 151: 591-593.

  103. Candy JM, Morrison C, Paton RD, Logan RW, Lawson R. Salicylate toxicity masquerading as malignant hyperthermia. Paediatr Anaesth. 1998; 8: 421-423.

  104. Chiaretti A, Schembri WD, Tortorolo L, Piastra M, Polidori G. Salicylate intoxication using a skin ointment. Acta Paediatr. 1997; 86: 330-331.

  105. Davies MG, Briffa DV, Greaves MW. Systemic toxicity from topically applied salicylic acid. BMJ. 1979; 1: 661.

  106. Péc J, Strmenová M, Palencárová E, Pullman R, Funiaková S, Visnovský P et al. Salicylate intoxication after use of topical salicylic acid ointment by a patient with psoriasis. Cutis. 1992; 50: 307-309.

  107. Van Scott EJ, Yu RJ. Hyperkeratinization, corneocyte cohesion, and alpha hydroxy acids. J Am Acad Dermatol. 1984; 11: 867-879.

  108. Tung RC, Bergfeld WF, Vidimos AT, Remzi BK. Alpha-hydroxy acid-based cosmetic procedures. Guidelines for patient management. Am J Clin Dermatol. 2000; 1: 81-88.

  109. Dréno B, Nocera T, Verrière F, Vienne MP, Ségard C, Vitse S et al. Topical retinaldehyde with glycolic acid: Study of tolerance and acceptability in association with anti-acne treatments in 1,709 patients. Dermatology. 2005; 210 (Suppl 1): 22-29.

  110. Poli F, Ribet V, Lauze C, Adhoute H, Morinet P. Efficacy and safety of 0.1% retinaldehyde/ 6% glycolic acid (diacneal) for mild to moderate acne vulgaris. A multicentre, double-blind, randomized, vehicle-controlled trial. Dermatology. 2005; 210 (Suppl 1): 14-21.

  111. Breneman DL, Ariano MC. Successful treatment of acne vulgaris in women with a new topical sodium sulfacetamide/sulfur lotion. Int J Dermatol. 1993; 32: 365-367.

  112. Tarimci N, Sener S, Kilinc T. Topical sodium sulfacetamide/sulfur lotion. J Clin Pharm Ther. 1997; 22: 301.

  113. Olansky S. Old drug-in a new system–revisited. Cutis. 1977; 19: 852-854.

  114. Genvert GI, Cohen EJ, Donnenfeld ED, Blecher MH. Erythema multiforme after use of topical sulfacetamide. Am J Ophthalmol. 1985; 99: 465-468.

  115. Rubin Z. Ophthalmic sulfonamide-induced Stevens-Johnson syndrome. Arch Dermatol. 1977; 113: 235-236.

  116. Akhavan A, Bershad S. Topical acne drugs: Review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol. 2003; 4: 473-492.

  117. Töpert M, Rach P, Siegmund F. Pharmacology and toxicology of azelaic acid. Acta Dermato-Venereológica. 1989; 143 (Suppl): 14-19.

  118. Leeming JP, Holland KT, Bojar RA. The in vitro antimicrobial effect of azelaic acid. Br J Dermatol. 1986; 115: 551-556.

  119. Gibson JR. Rationale for the development of new topical treatments for acne vulgaris. Cutis. 1996; 57(Suppl 1): 13-19.

  120. Carmichael AJ, Marks R, Graupe KA, Zaumseil RP. Topical azelaic acid in the treatment of rosacea. J Dermatol Treat. 1993; 4 (Suppl 1): 19-22.

  121. Gollnick H, Schramm M. Topical therapy in acné. J Eur Acad Dermatol Venereol. 1998; 11 (Suppl.1): S8-12, S28-29.

  122. Purdy S, DeBeker D. Acne vulgaris. Clin Evidence. 2008; 5: 1714-1748.

  123. Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Derm Venereol. Suppl (Stockh). 1989; 143: 35-39.

  124. Cunliffe WJ, Holland KT. Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Derm Venereol Suppl (Stockh). 1989; 143: 31-34.

  125. Iraji F, Sadeghinia A, Shahmoradi Z, Siadat AH, Jooya A. Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Indian J Dermatol Venereol Leprol. 2007; 73: 94-96.

  126. Cavicchini S, Caputo R. Long-term treatment of acne with 20% azelaic acid cream. Acta Derm Venereol Suppl (Stockh). 1989; 143: 40-44.

  127. Shalita AR. Comparison of 2% salicylic acid alcoholic detergent solution (Stridex) with benzoyl peroxide 5% cream. Submitted to the FDA, April 12, 1982, 2008. Data on file, Glenbrook Laboratories.

  128. Korting HC, Borelli C, Schöllmann C. Acne vulgaris. Role of cosmetics. Hautarzt. 2010; 61: 126-131.

  129. Bartenjev I, Oremović L, Rogl Butina M, Sjerobabski MI, Bouloc A, Voda K, Šitum M. Topical effectiveness of a cosmetic skincare treatment for acne-prone skin: a clinical study. Clin Plast Surg. 2011; 38: 397-407.

  130. Guerra-Tapia A, Aizpun PM. Cosmética en acné. Editorial Permanyer S.L. Barcelona. 2003.

  131. González-Guerra E, Guerra-Tapia A. Aplicación de los cosmecéuticos a la práctica dermatológica. Monogr Dermatol. 2012; 25: 63-67.

  132. Draelos ZD. The art and science of new advances in cosmeceuticals. Acta Dermatovenerol Alp Panonica Adriat. 2011; 20: 55-62.

  133. Goodman G. Cleansing and moisturizing in acne patients. Am J Clin Dermatol. 2009; 10 (Suppl 1): 1-6.

  134. Herane MI, Fuenzalida H, Zegpi E, De Pablo C, Espadas MJ, Trullás C et al. Specific gel-cream as adjuvant to oral isotretinoin improved hydration and prevented TEWL increase-a double-blind, randomized, placebo-controlled study. J Cosmet Dermatol. 2009; 8: 181-185.

  135. Allen HB, LoPresti PJ. Acne vulgaris aggravated by sunlight. Cutis. 1980; 26: 254-256.

  136. Guerra Tapia A, González-Guerra E. Maquillaje terapéutico. Algo más que un gesto estético. Salud Estética. 2011; 11: 20-24.

  137. Matsuoka Y, Yoneda K, Sadahira C, Katsuura J, Moriue T, Kubota Y. Effects of skin care and makeup under instructions from dermatologists on the quality of life of female patients with acne vulgaris. J Dermatol. 2006; 33: 745-752.



>Revistas >Medicina Cutánea Ibero-Latino-Americana >Año2015, No. 2
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019